N 11 individuals Function Total payments received Total drug price Patient count

As we did not include research reimbursement or equity, however, these differences cannot be attributed directly to greater research involvement.N 11 individuals Function Total payments received Total drug price Patient count^ Total claims Branded claims# Generic claims# 102,954 90,426 141,264 11,430 314,067 34,863 n 346,074 346,074 311,211 346,074 210,584 300,921 imply 83.11 172,723.30 199 2,428 757 two,156 29.eight 26.1 40.eight three.three 90.8 10.1 SD 201.34 274,598.60 206 4089 1119 3308 10,917 9,975 18,030 914 35,935 1,061 n 39,836 39,836 38,775 39,836 29,604 37,465 mean 6,341.64 454,154.40 316 five,217 1,629 four,087 27.four 25.0 45.3 2.3 90.two two.7 SD 29,474.29 567,649.10 285 6,810 2,120 5,072 78,065 77,611 110,276 73,048 7,074 22.six 22.four 31.9 21.1 two.0 7,563 8,799 15,619 7,337 518 19.0 22.1 39.2 18.4 1.3 n 118,474 pct 34.2 Top rated Payment Quintile (N = 39,836) n 7,749 pct 19.5*All contrasts considerable at pNs a major challenge in studies primarily based on these measures. Nevertheless others, however, expense title= 17470919.2015.1029593 is driven by a greater proportion of branded prescriptions.